ES2530843T3 - Métodos basados en microARN para el diagnóstico de cáncer de páncreas - Google Patents

Métodos basados en microARN para el diagnóstico de cáncer de páncreas Download PDF

Info

Publication number
ES2530843T3
ES2530843T3 ES12154341T ES12154341T ES2530843T3 ES 2530843 T3 ES2530843 T3 ES 2530843T3 ES 12154341 T ES12154341 T ES 12154341T ES 12154341 T ES12154341 T ES 12154341T ES 2530843 T3 ES2530843 T3 ES 2530843T3
Authority
ES
Spain
Prior art keywords
pancreatic cancer
diagnosis
based methods
subject
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12154341T
Other languages
English (en)
Inventor
Carlo Croce
George Calin
Stefano Volinia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ohio State University Research Foundation
Original Assignee
Ohio State University Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio State University Research Foundation filed Critical Ohio State University Research Foundation
Application granted granted Critical
Publication of ES2530843T3 publication Critical patent/ES2530843T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/12—Applications; Uses in screening processes in functional genomics, i.e. for the determination of gene function
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/10—Production naturally occurring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Un método para diagnosticar si un sujeto tiene un cáncer sólido que comprende: medir el nivel de al menos un producto génico de miR-30c en una muestra de ensayo de tejido pancreático del sujeto, en donde una alteración en el nivel del producto génico de miR-3c0 en la muestra de ensayo, en relación con el nivel del producto génico de miR-30c en una muestra de control, es indicativa de que el sujeto tiene cáncer de páncreas.
ES12154341T 2006-01-05 2007-01-03 Métodos basados en microARN para el diagnóstico de cáncer de páncreas Active ES2530843T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75658506P 2006-01-05 2006-01-05

Publications (1)

Publication Number Publication Date
ES2530843T3 true ES2530843T3 (es) 2015-03-06

Family

ID=38256892

Family Applications (22)

Application Number Title Priority Date Filing Date
ES12154339.1T Active ES2545119T3 (es) 2006-01-05 2007-01-03 Métodos basados en microARN y composiciones para el diagnóstico y el tratamiento de cánceres sólidos
ES12154345T Active ES2461189T3 (es) 2006-01-05 2007-01-03 Métodos basados en microARN y composiciones para el diagnóstico y el tratamiento de cánceres sólidos de mama o pulmón
ES12154350.8T Active ES2525584T3 (es) 2006-01-05 2007-01-03 Métodos basados en microARN y composiciones para el diagnóstico y el tratamiento de cánceres sólidos
ES12154337.5T Active ES2546425T3 (es) 2006-01-05 2007-01-03 Métodos basados en microARN y composiciones para el diagnóstico y el tratamiento de cánceres sólidos
ES12154344T Active ES2465600T3 (es) 2006-01-05 2007-01-03 Métodos basados en microARN y composiciones para el diagnóstico y tratamiento de cánceres sólidos del páncreas
ES12154343.3T Active ES2604324T3 (es) 2006-01-05 2007-01-03 Métodos y composiciones basadas en microARN para el diagnóstico y el tratamiento de cánceres sólidos
ES12154349T Active ES2531052T3 (es) 2006-01-05 2007-01-03 Métodos y composiciones basados en microARN para el diagnóstico de cánceres de mama
ES12154348.2T Active ES2536422T3 (es) 2006-01-05 2007-01-03 Métodos y composiciones basados en microARN para el diagnóstico y tratamiento de cáncer pancreático
ES12154321.9T Active ES2545360T3 (es) 2006-01-05 2007-01-03 Métodos basados en microARN y composiciones para el diagnóstico y tratamiento de cánceres sólidos
ES12154315.1T Active ES2527592T3 (es) 2006-01-05 2007-01-03 Métodos basados en microARN para el diagnóstico del cáncer de colon
ES12154332.6T Active ES2526787T3 (es) 2006-01-05 2007-01-03 Métodos basados en microARN para el diagnóstico de cánceres de colon, páncreas y estómago
ES12154354.0T Active ES2536437T3 (es) 2006-01-05 2007-01-03 Métodos basados en microARN para el diagnóstico de cáncer de estómago
ES12154307T Active ES2440787T3 (es) 2006-01-05 2007-01-03 Métodos basados en microARN y composiciones para el diagnóstico y el tratamiento de cánceres sólidos
ES12154353.2T Active ES2536423T3 (es) 2006-01-05 2007-01-03 Métodos basados en microARN para el diagnóstico de cáncer de próstata
ES12154346.6T Active ES2537880T3 (es) 2006-01-05 2007-01-03 Métodos basados en microARN para el diagnóstico de cáncer de próstata o cánceres de estómago
ES12154327.6T Active ES2544713T3 (es) 2006-01-05 2007-01-03 Métodos basados en microARN y composiciones para el diagnóstico y tratamiento de cánceres sólidos
ES12154304.5T Active ES2490995T3 (es) 2006-01-05 2007-01-03 Métodos basados en microARN y composiciones para el diagnóstico y el tratamiento de cánceres sólidos
ES07717903.4T Active ES2508893T3 (es) 2006-01-05 2007-01-03 Métodos basados en microARN para el diagnóstico de cánceres de estómago
ES12154322.7T Active ES2547805T3 (es) 2006-01-05 2007-01-03 Métodos basados en microARN y composiciones para el diagnóstico y el tratamiento de cánceres sólidos
ES12154334.2T Active ES2545118T3 (es) 2006-01-05 2007-01-03 Métodos basados en microARN y composiciones para el diagnóstico y tratamiento de cánceres sólidos
ES12154341T Active ES2530843T3 (es) 2006-01-05 2007-01-03 Métodos basados en microARN para el diagnóstico de cáncer de páncreas
ES12154342.5T Active ES2557411T3 (es) 2006-01-05 2007-01-03 Métodos y composiciones basados en microARN para el diagnóstico y el tratamiento de cánceres sólidos

Family Applications Before (20)

Application Number Title Priority Date Filing Date
ES12154339.1T Active ES2545119T3 (es) 2006-01-05 2007-01-03 Métodos basados en microARN y composiciones para el diagnóstico y el tratamiento de cánceres sólidos
ES12154345T Active ES2461189T3 (es) 2006-01-05 2007-01-03 Métodos basados en microARN y composiciones para el diagnóstico y el tratamiento de cánceres sólidos de mama o pulmón
ES12154350.8T Active ES2525584T3 (es) 2006-01-05 2007-01-03 Métodos basados en microARN y composiciones para el diagnóstico y el tratamiento de cánceres sólidos
ES12154337.5T Active ES2546425T3 (es) 2006-01-05 2007-01-03 Métodos basados en microARN y composiciones para el diagnóstico y el tratamiento de cánceres sólidos
ES12154344T Active ES2465600T3 (es) 2006-01-05 2007-01-03 Métodos basados en microARN y composiciones para el diagnóstico y tratamiento de cánceres sólidos del páncreas
ES12154343.3T Active ES2604324T3 (es) 2006-01-05 2007-01-03 Métodos y composiciones basadas en microARN para el diagnóstico y el tratamiento de cánceres sólidos
ES12154349T Active ES2531052T3 (es) 2006-01-05 2007-01-03 Métodos y composiciones basados en microARN para el diagnóstico de cánceres de mama
ES12154348.2T Active ES2536422T3 (es) 2006-01-05 2007-01-03 Métodos y composiciones basados en microARN para el diagnóstico y tratamiento de cáncer pancreático
ES12154321.9T Active ES2545360T3 (es) 2006-01-05 2007-01-03 Métodos basados en microARN y composiciones para el diagnóstico y tratamiento de cánceres sólidos
ES12154315.1T Active ES2527592T3 (es) 2006-01-05 2007-01-03 Métodos basados en microARN para el diagnóstico del cáncer de colon
ES12154332.6T Active ES2526787T3 (es) 2006-01-05 2007-01-03 Métodos basados en microARN para el diagnóstico de cánceres de colon, páncreas y estómago
ES12154354.0T Active ES2536437T3 (es) 2006-01-05 2007-01-03 Métodos basados en microARN para el diagnóstico de cáncer de estómago
ES12154307T Active ES2440787T3 (es) 2006-01-05 2007-01-03 Métodos basados en microARN y composiciones para el diagnóstico y el tratamiento de cánceres sólidos
ES12154353.2T Active ES2536423T3 (es) 2006-01-05 2007-01-03 Métodos basados en microARN para el diagnóstico de cáncer de próstata
ES12154346.6T Active ES2537880T3 (es) 2006-01-05 2007-01-03 Métodos basados en microARN para el diagnóstico de cáncer de próstata o cánceres de estómago
ES12154327.6T Active ES2544713T3 (es) 2006-01-05 2007-01-03 Métodos basados en microARN y composiciones para el diagnóstico y tratamiento de cánceres sólidos
ES12154304.5T Active ES2490995T3 (es) 2006-01-05 2007-01-03 Métodos basados en microARN y composiciones para el diagnóstico y el tratamiento de cánceres sólidos
ES07717903.4T Active ES2508893T3 (es) 2006-01-05 2007-01-03 Métodos basados en microARN para el diagnóstico de cánceres de estómago
ES12154322.7T Active ES2547805T3 (es) 2006-01-05 2007-01-03 Métodos basados en microARN y composiciones para el diagnóstico y el tratamiento de cánceres sólidos
ES12154334.2T Active ES2545118T3 (es) 2006-01-05 2007-01-03 Métodos basados en microARN y composiciones para el diagnóstico y tratamiento de cánceres sólidos

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES12154342.5T Active ES2557411T3 (es) 2006-01-05 2007-01-03 Métodos y composiciones basados en microARN para el diagnóstico y el tratamiento de cánceres sólidos

Country Status (8)

Country Link
US (24) US8148069B2 (es)
EP (31) EP2484782B1 (es)
JP (4) JP5395439B2 (es)
CN (3) CN101389770B (es)
AU (1) AU2007205163B2 (es)
CA (1) CA2633754C (es)
ES (22) ES2545119T3 (es)
WO (1) WO2007081740A2 (es)

Families Citing this family (309)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2530157B1 (en) * 2003-07-31 2016-09-28 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of miRNAs
CA2554818A1 (en) 2004-02-09 2005-08-25 Thomas Jefferson University Diagnosis and treatment of cancers with microrna located in or near cancer-associated chromosomal features
EP2290073A3 (en) 2004-05-28 2011-08-31 Asuragen, Inc. Methods and compositions involving microRNA
CA2857878A1 (en) 2004-11-12 2006-12-28 Asuragen, Inc. Methods and compositions involving mirna and mirna inhibitor molecules
WO2006133022A2 (en) * 2005-06-03 2006-12-14 The Johns Hopkins University Compositions and methods for decreasing microrna expression for the treatment of neoplasia
CN103820562B (zh) * 2005-08-01 2015-05-13 俄亥俄州立大学研究基金会 用于乳腺癌的诊断、预后和治疗的基于MicroRNA的方法和组合物
CA2621441C (en) 2005-09-12 2014-05-20 The Ohio State University Research Foundation Compositions and methods for the diagnosis and therapy of bcl2-associated cancers
US8445198B2 (en) * 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
EP2502630B1 (en) 2006-01-05 2015-03-11 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
EP2484782B1 (en) * 2006-01-05 2015-11-18 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers
CN101384273B (zh) 2006-01-05 2013-07-10 俄亥俄州立大学研究基金会 胰腺内分泌和腺泡肿瘤中的微小rna表达异常
EP2369013A1 (en) 2006-03-20 2011-09-28 The Ohio State University Research Foundation Micro-RNA fingerprints during human megakaryocytopoiesis
EP2455493B1 (en) 2006-07-13 2014-01-08 The Ohio State University Research Foundation Micro-RNA-based methods and compositions for the diagnosis and treatment of colon related diseases
CA2663027A1 (en) 2006-09-19 2008-08-14 The Ohio State University Research Foundation Tcl1 expression in chronic lymphocytic leukemia (cll) regulated by mir-29 and mir-181
US8252538B2 (en) 2006-11-01 2012-08-28 The Ohio State University MicroRNA expression signature for predicting survival and metastases in hepatocellular carcinoma
US8975026B2 (en) * 2007-01-16 2015-03-10 Somalogic, Inc. Method for generating aptamers with improved off-rates
CN103555825B (zh) 2007-01-31 2015-09-30 俄亥俄州立大学研究基金会 用于急性髓细胞白血病(aml)的诊断、预后和治疗的基于微rna的方法和组合物
WO2008136971A1 (en) * 2007-04-30 2008-11-13 The Ohio State University Research Foundation Methods for differentiating pancreatic cancer from normal pancreatic function and/or chronic pancreatitis
US8697672B2 (en) 2007-05-16 2014-04-15 California Institute Of Technology Microrna inhibition for the treatment of inflammation and myeloproliferative disorders
WO2008144724A1 (en) * 2007-05-21 2008-11-27 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
CN101711287B (zh) 2007-06-08 2016-04-27 由卫生与公众服务部代表的美利坚合众国政府 确定肝细胞癌亚型和检测肝癌干细胞的方法
AU2008266014B2 (en) 2007-06-15 2013-06-06 The Ohio State University Research Foundation Oncogenic ALL-1 fusion proteins for targeting drosha-mediated microRNA processing
EP2176425A2 (en) * 2007-07-06 2010-04-21 Koninklijke Nederlandse Akademie van Wetenschappen Small rna molecules, precursors thereof, means and methods for detecting them, and uses thereof in typing samples
US8367318B2 (en) 2007-07-23 2013-02-05 Dharmacon, Inc. Screening of micro-RNA cluster inhibitor pools
ES2621161T3 (es) 2007-07-31 2017-07-03 The Board Of Regents Of The University Of Texas System Familia de micro-ARN que modula la fibrosis y usos de la misma
CN101809169B (zh) 2007-07-31 2013-07-17 俄亥俄州立大学研究基金会 通过靶向dnmt3a和dnmt3b恢复甲基化的方法
EP2173908B1 (en) 2007-08-03 2016-01-06 The Ohio State University Research Foundation Ultraconserved regions encoding ncrnas
US20120070442A1 (en) * 2007-08-09 2012-03-22 The Regents Of The University Of Colorado, A Body Corporate Methods and compositions for treating cancer
US8716255B2 (en) 2007-08-10 2014-05-06 British Columbia Cancer Agency Branch Microrna compositions and methods for the treatment of myelogenous leukemia
CA2926831A1 (en) 2007-08-22 2009-02-26 The Ohio State University Research Foundation Methods and compositions for inducing deregulation of epha7 and erk phosphorylation in human acute leukemias
WO2009024790A1 (en) * 2007-08-23 2009-02-26 Isis Innovation Limited Method and kit for the prognosis of cancer by determining the level of mirna-210
CA2698771A1 (en) * 2007-09-06 2009-03-12 The Ohio State University Research Foundation Microrna signatures in human ovarian cancer
EP2610342B1 (en) * 2007-09-14 2016-05-04 The Ohio State University Research Foundation MiRNA Expression in Human Peripheral Blood Microvesicles and uses Thereof
EP2198050A1 (en) 2007-09-14 2010-06-23 Asuragen, INC. Micrornas differentially expressed in cervical cancer and uses thereof
US20090136957A1 (en) * 2007-09-15 2009-05-28 Irena Ivanovska Methods and compositions for regulating cell cycle progression via the miR-106B family
WO2009044899A1 (ja) * 2007-10-03 2009-04-09 Kyowa Hakko Kirin Co., Ltd. 細胞の増殖を制御する核酸
CA2703707A1 (en) 2007-10-26 2009-04-30 The Ohio State University Research Foundation Methods for identifying fragile histidine triad (fhit) interaction and uses thereof
EP2215263A1 (en) 2007-10-30 2010-08-11 Veridex LLC Process for predicting the prognosis of squamous cell lung cancer
CN101424640B (zh) * 2007-11-02 2012-07-25 江苏命码生物科技有限公司 血清中微小核糖核酸的检测方法和用于检测的试剂盒、生物芯片及其制作和应用方法
WO2009070805A2 (en) * 2007-12-01 2009-06-04 Asuragen, Inc. Mir-124 regulated genes and pathways as targets for therapeutic intervention
US7964354B2 (en) 2007-12-20 2011-06-21 Celgene Corporation Use of micro-RNA as a biomarker of immunomodulatory drug activity
WO2009082744A2 (en) * 2007-12-22 2009-07-02 Sloan-Kettering Institute For Cancer Research Prognosis and interference-mediated treatment of breast cancer
JP5116026B2 (ja) * 2008-01-23 2013-01-09 富士フイルム株式会社 癌の検出方法および癌抑制剤
CA2716906A1 (en) * 2008-02-28 2009-09-03 The Ohio State University Research Foundation Microrna-based methods and compositions for the diagnosis, prognosis and treatment of gastric cancer
US20110054009A1 (en) * 2008-02-28 2011-03-03 The Ohio State University Research Foundation MicroRNA-Based Methods and Compositions for the Diagnosis, Prognosis and Treatment of Prostate Related Disorders
US20090233297A1 (en) * 2008-03-06 2009-09-17 Elizabeth Mambo Microrna markers for recurrence of colorectal cancer
US8258111B2 (en) 2008-05-08 2012-09-04 The Johns Hopkins University Compositions and methods related to miRNA modulation of neovascularization or angiogenesis
WO2009143379A2 (en) * 2008-05-21 2009-11-26 Fred Hutchinson Cancer Research Center Use of extracellular rna to measure disease
EP2123258A1 (en) 2008-05-23 2009-11-25 Liplasome Pharma A/S Liposomes for drug delivery
CA2725978A1 (en) 2008-05-28 2009-12-03 Genomedx Biosciences, Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
US9217155B2 (en) 2008-05-28 2015-12-22 University Of Massachusetts Isolation of novel AAV'S and uses thereof
US9765334B2 (en) * 2008-06-01 2017-09-19 Rosetta Genomics, Ltd. Compositions and methods for prognosis of gastric cancer
CA2727633A1 (en) 2008-06-11 2009-12-17 Xin W. Wang Use of mir-26 family as a predictive marker for hepatocellular carcinoma and responsiveness to therapy
CN105624193B (zh) * 2008-09-26 2021-07-13 索元生物医药(美国)有限公司 重组载体
WO2010050328A1 (ja) * 2008-10-27 2010-05-06 国立がんセンター総長が代表する日本国 腫瘍の転移抑制剤
GB2465088C (en) * 2008-10-30 2016-01-27 Caris Mpi Inc miRNA expression in the characterisation and classification of cancer
CN102308004A (zh) 2008-10-30 2012-01-04 卡里斯生命科学卢森堡控股有限责任公司 评价rna图案的方法
US9074206B2 (en) 2008-11-13 2015-07-07 Fudan University Compositions and methods for micro-RNA expression profiling of colorectal cancer
WO2010058393A2 (en) * 2008-11-20 2010-05-27 Rosetta Genomics Ltd. Compositions and methods for the prognosis of colon cancer
EP2373815A4 (en) * 2008-12-05 2012-09-26 Univ Ohio State Res Found METHODS AND COMPOSITIONS BASED ON MICROARN FOR THE DIAGNOSIS AND TREATMENT OF OVARIAN CANCER
AU2009322137B2 (en) * 2008-12-05 2015-09-10 Whitehead Institute For Biomedical Research Compositions and methods relating to miR-31
EP2358902A1 (en) * 2008-12-10 2011-08-24 Universität Regensburg Compositions and methods for micro-rna expression profiling of cancer stem cells
EP2199412A1 (en) * 2008-12-10 2010-06-23 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Compositions and methods for micro-RNA expression profiling of cancer stem cells
CN101475984A (zh) 2008-12-15 2009-07-08 江苏命码生物科技有限公司 一种非小细胞肺癌检测标记物及其检测方法、相关生物芯片和试剂盒
EP2196542A1 (en) * 2008-12-15 2010-06-16 Koninklijke Philips Electronics N.V. Compositions and methods for micro-rna expression profiling of colorectal cancer
JP2012515532A (ja) 2009-01-20 2012-07-12 ラモット アット テル アビブ ユニバーシティ， リミテッド Ｍｉｒ−２１プロモーター駆動性標的がん治療
WO2010094155A1 (en) * 2009-02-23 2010-08-26 Capitalbio Corporation Methods and compositions diagnosing lung cancer, determining prognosis, and improving patient survival
WO2010099342A2 (en) * 2009-02-25 2010-09-02 Cepheid Methods of detecting lung cancer
EP2414549A4 (en) 2009-03-31 2013-08-28 Us Health DIFFERENTIALLY EXPRESSED MICRO-RNAS AS BIOMARKERS FOR THE DIAGNOSIS AND TREATMENT OF SJÖGREN SYNDROME
WO2010119698A1 (ja) * 2009-04-16 2010-10-21 学校法人 慶應義塾 頭頸部腫瘍増殖抑制剤
ES2786039T3 (es) 2009-04-30 2020-10-08 Ospedale San Raffaele Srl Vector génico
WO2010135692A2 (en) * 2009-05-22 2010-11-25 Asuragen, Inc. Mirna biomarkers of prostate disease
WO2010138263A2 (en) 2009-05-28 2010-12-02 University Of Massachusetts Novel aav 's and uses thereof
US20100322909A1 (en) * 2009-06-17 2010-12-23 The University Of Pittsburgh - Of The Commonwealth System Of Higher Education Th1-associated micrornas and their use for tumor immunotherapy
US20120190729A1 (en) * 2009-07-27 2012-07-26 The Regents Of The University Of Colorado A Body Corporate Mirna inhibition of six1 expression
CN101988061A (zh) * 2009-07-30 2011-03-23 江苏命码生物科技有限公司 乳腺癌检测标记物及其检测方法、试剂盒和生物芯片
EP2283846A1 (en) * 2009-08-12 2011-02-16 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. miRNA compounds for treatment of prostate carcinoma
EP2910648A1 (en) * 2009-08-24 2015-08-26 National University Corporation Kanazawa University Detection of biliary tract cancer by gene expression profiling
DK177532B1 (en) 2009-09-17 2013-09-08 Bio Bedst Aps Medical use of sPLA2 hydrolysable liposomes
WO2011040525A1 (ja) * 2009-09-30 2011-04-07 財団法人ヒューマンサイエンス振興財団 大腸がん検査マーカーおよび大腸がんの検査方法
EP2504452A4 (en) 2009-11-23 2014-06-11 Univ Ohio State Res Found MATERIALS AND METHODS FOR INFLUENCING GROWTH, MIGRATION AND INVASION OF TUMOR CELLS
WO2011076144A1 (en) * 2009-12-24 2011-06-30 Fudan University Compositions and methods for microrna expession profiling in plasma of lung cancer
CN101942502B (zh) * 2009-12-24 2014-09-17 北京命码生科科技有限公司 胰腺癌标记物及其检测方法、试剂盒和生物芯片
CN102770561B (zh) * 2009-12-24 2015-05-06 复旦大学 用于诊断不同亚型肺癌的基于组织的微-rna方法
WO2011076145A1 (en) * 2009-12-24 2011-06-30 Fudan University Tissue-based micro-rna methods for diagnosis of different subtypes of lung cancer
EP2518158B1 (en) 2009-12-24 2016-09-14 Micromedmark Biotech Co., Ltd Pancreatic cancer markers and detecting methods
WO2011088309A1 (en) * 2010-01-14 2011-07-21 Regulus Therapeutics Inc. Microrna compositions and methods
CN101875973B (zh) * 2010-04-01 2013-01-09 华中农业大学 与猪免疫性状相关的小rna分子标记与应用
US20130131148A1 (en) 2010-04-12 2013-05-23 Noam Shomron Micro-rna for cancer diagnosis, prognosis and therapy
US9272053B2 (en) 2010-04-23 2016-03-01 University Of Massachusetts AAV-based treatment of cholesterol-related disorders
WO2011135459A2 (en) 2010-04-29 2011-11-03 Medical Prognosis Institute A/S Methods and devices for predicting treatment efficacy
CN102242080B (zh) * 2010-05-13 2014-03-05 北京大学第三医院 miR-24用于治疗或诊断心衰或患心衰倾向或者改善心肌细胞功能的方法
CN103080334B (zh) * 2010-06-04 2016-05-04 复旦大学 用于诊断早期结直肠癌及高级腺瘤的微rna生物标记及方法
WO2011156777A1 (en) 2010-06-10 2011-12-15 Fred Hutchinson Cancer Research Center Use of blood mir-210 for cancer prognosis
EP3228629A1 (en) * 2010-06-16 2017-10-11 Minerva Biotechnologies Corporation Reprogramming cancer cells
NZ605420A (en) 2010-07-06 2015-02-27 Interna Technologies Bv Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
CA2804271A1 (en) 2010-07-08 2012-01-12 Takeda Pharmaceutical Company Limited Prophylactic or therapeutic agent for diabetes
JP5099571B2 (ja) 2010-07-12 2012-12-19 国立大学法人鳥取大学 ｍｉＲＮＡ導入による新規ｈｉＰＳＣ作製法
US8980549B2 (en) 2010-08-01 2015-03-17 Ramot At Tel Aviv University Ltd. MicroRNA patterns for the diagnosis, prognosis and treatment of melanoma
CN102018965A (zh) * 2010-09-17 2011-04-20 天津医科大学 miRNA-10a在制备抑制结肠癌的侵袭和转移药物中的应用
CN102406653B (zh) * 2010-09-21 2015-05-06 中国人民解放军第二军医大学 一种miRNA的抗病毒作用、实施方法及用途
US8933051B2 (en) 2010-09-30 2015-01-13 University Of Zurich Treatment of B-cell lymphoma with microRNA
EP3075396A1 (en) * 2010-10-17 2016-10-05 Yeda Research and Development Co. Ltd. Methods and compositions for the treatment of insulin-associated medical conditions
CN102031261B (zh) * 2010-10-27 2015-04-22 南京医科大学 一种与妊娠期糖尿病相关的血清/血浆miRNA标志物及其应用
CN103648505B (zh) 2010-11-12 2016-09-28 俄亥俄州立大学研究基金会 与微rna-21、错配修复和结肠直肠癌相关的材料和方法
BR112013011942A2 (pt) 2010-11-15 2016-11-01 Univ Michigan formulação, forma de dosagem de droga para administração transmucosa oral, sistema transmucoso de fornecimento de droga, método de tratamento e profilaxia de uma doença ou distúrbio, método de tratamento, formulação, método para tratamento ou prevenção de carcinoma de célula escamosa de cabeça e pescoço (hnscc), método para quimioprevenção de um câncer oral ou condição pré-cancerosa, método para aumentar a concentração de uma composição de retinida, método de tratamento e profilaxia de uma doença ou condição, método de ratamento de um sujeito apresentando uma condição médica sintomática, método de tratamento de um câncer oral ou condição pré-cancerosa num paciente, método para fazer um sistema de fornecimento de droga bucal, método para aumentar a liberação e permeação de uma composição de retinida.
US20130267443A1 (en) 2010-11-19 2013-10-10 The Regents Of The University Of Michigan ncRNA AND USES THEREOF
ES2632145T3 (es) * 2010-12-01 2017-09-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Modo de predicción del desenlace de un cáncer analizando la expresión de miARN
CN102140466B (zh) * 2010-12-30 2013-03-27 苏州吉玛基因股份有限公司 人miR-1825反义核酸及其应用
CN102140467B (zh) * 2010-12-30 2013-05-15 苏州吉玛基因股份有限公司 人miR-365反义核酸及其应用
EP2474617A1 (en) 2011-01-11 2012-07-11 InteRNA Technologies BV Mir for treating neo-angiogenesis
CN102146412B (zh) * 2011-01-11 2012-10-03 中山大学 一种小分子非编码RNA 基因hsa-miR-29b 及其应用
US20120244530A1 (en) 2011-01-26 2012-09-27 Cepheid Methods of detecting lung cancer
JP2014506789A (ja) 2011-02-03 2014-03-20 マーナ セラピューティクス インコーポレイテッド ｍｉＲ−１２４の合成模倣体
WO2012106591A1 (en) 2011-02-03 2012-08-09 Mirna Therapeutics, Inc. Synthetic mimics of mir-34
HUE045731T2 (hu) * 2011-02-07 2020-01-28 Gabriella Sozzi Mikro-RNS biomarkerek tüdõtumor diagnosztizálásához és/vagy kockázatának azonosításához
CA2828772A1 (en) 2011-03-07 2012-09-13 The Ohio State University Mutator activity induced by microrna-155 (mir-155) links inflammation and cancer
JP6196163B2 (ja) 2011-03-17 2017-09-13 ミネルバ バイオテクノロジーズ コーポレーション 多能性幹細胞を作製する方法
JP2014515024A (ja) 2011-04-12 2014-06-26 ベス イスラエル デアコネス メディカル センター， インコーポレイテッド マイクロｒｎａ阻害剤および疾患におけるその使用
EP2699666B1 (en) * 2011-04-18 2016-10-05 DiamiR, LLC miRNA-BASED UNIVERSAL SCREENING TEST (UST)
US9226976B2 (en) 2011-04-21 2016-01-05 University Of Massachusetts RAAV-based compositions and methods for treating alpha-1 anti-trypsin deficiencies
WO2012174293A2 (en) 2011-06-14 2012-12-20 Nestec Sa Methods for identifying inflammatory bowel disease patients with dysplasia or cancer
WO2013040251A2 (en) 2011-09-13 2013-03-21 Asurgen, Inc. Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease
JPWO2013038737A1 (ja) 2011-09-16 2015-03-23 Ｌｓｉｐファンド運営合同会社 膀胱癌細胞の検出方法、膀胱癌細胞の検出方法に用いるプライマー及び膀胱癌マーカ
EP2766500A4 (en) 2011-10-14 2015-10-14 Univ Ohio State METHOD AND MATERIALS IN CONNECTION WITH EGG CANCER
WO2013067048A1 (en) * 2011-10-31 2013-05-10 The Ohio State University Materials and methods related to mir-221 and hepatocellular carcinoma
AU2012347498A1 (en) * 2011-12-10 2014-06-26 Ohio State Innovation Foundation MiRNAs useful to reduce lung cancer tumorigenesis and chemotherapy resistance and related compositons and methods
CA2859430A1 (en) * 2011-12-13 2013-06-20 Ohio State Innovation Foundation Methods and compositions related to mir-21 and mir-29a, exosome inhibition, and cancer metastasis
CN102533976A (zh) * 2011-12-15 2012-07-04 苏州福英基因科技有限公司 各种癌症病理演变前期microrna-21原位杂交检测试剂盒及检测方法和应用
CN102533978A (zh) * 2011-12-15 2012-07-04 苏州福英基因科技有限公司 各种癌症病理演变前期microrna-373水平原位杂交检测试剂盒及检测方法和应用
CN102533977A (zh) * 2011-12-15 2012-07-04 苏州福英基因科技有限公司 各种癌症病理演变前期microrna-372水平原位杂交检测试剂盒及检测方法和应用
CN102533980A (zh) * 2011-12-15 2012-07-04 苏州福英基因科技有限公司 各种癌症病理演变前期microrna-10b水平原位杂交检测试剂盒及检测方法和应用
WO2013095941A1 (en) * 2011-12-19 2013-06-27 Valley Health System Methods and kits for detecting subjects at risk of having cancer
CN102533983A (zh) * 2011-12-19 2012-07-04 苏州福英基因科技有限公司 癌症病理演变前期microrna-330水平原位杂交检测试剂盒及检测方法和应用
CN102443644A (zh) * 2011-12-20 2012-05-09 苏州福英基因科技有限公司 结肠癌病理演变前期microrna-29a水平原位杂交检测试剂盒及检测方法和应用
CN102559884A (zh) * 2011-12-27 2012-07-11 芮屈生物技术（上海）有限公司 各种癌症病理演变前期let-7mirna水平原位杂交检测试剂盒及检测方法和应用
EP2809810B1 (en) 2012-01-06 2019-11-13 Viomics Inc. System and method of detecting rnas altered by lung cancer in peripheral blood
US8859202B2 (en) 2012-01-20 2014-10-14 The Ohio State University Breast cancer biomarker signatures for invasiveness and prognosis
WO2013155980A1 (zh) * 2012-04-19 2013-10-24 中国科学院上海生命科学研究院 自身免疫性疾病相关的microRNA及其应用
CN102676524B (zh) * 2012-05-16 2013-04-03 北京旷博生物技术有限公司 乳腺癌分子标志物miR-147a
CN102743765A (zh) * 2012-05-24 2012-10-24 上海大学 非小细胞肺癌中miR-10a基因的应用
WO2014012047A1 (en) * 2012-07-12 2014-01-16 University Of Louisville Research Foundation, Inc. Systems and methods for diagnosis, prognosis, and treatment of cancer
ES3015226T3 (en) 2012-08-16 2025-04-30 Veracyte Sd Inc Prostate cancer prognosis using biomarkers
CN102816862A (zh) * 2012-09-19 2012-12-12 南开大学 miRNA 222在前列腺癌血清学诊断试剂盒中的应用
CN102827943A (zh) * 2012-09-19 2012-12-19 南开大学 miRNA 320a在前列腺癌血清学诊断试剂盒中的应用
EP2711430A1 (en) * 2012-09-24 2014-03-26 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. MicroRNA based method for diagnosis of colorectal tumors and of metastasis
CN104994861B (zh) 2012-10-18 2019-10-11 西澳大学 使用miRNA的癌症疗法
US11065311B2 (en) 2012-10-25 2021-07-20 Denovo Biopharma Llc Retroviral vector with mini-promoter cassette
ES2921623T3 (es) 2012-11-26 2022-08-30 Modernatx Inc ARN modificado terminalmente
EP2931319B1 (en) 2012-12-13 2019-08-21 ModernaTX, Inc. Modified nucleic acid molecules and uses thereof
EP2746406B1 (en) 2012-12-18 2017-08-23 Samsung Electronics Co., Ltd. Composition and kit for diagnosing breast cancer including miRNAs within vesicle, and method of diagnosing breast cancer using the same
JP2016504050A (ja) 2013-01-17 2016-02-12 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 細胞表現型の改変のためのシグナルセンサーポリヌクレオチド
CN103224933A (zh) * 2013-02-22 2013-07-31 上海大学 非小细胞肺癌中miR-34a基因的应用
US20160017326A1 (en) * 2013-03-14 2016-01-21 The Trustees Of Princeton University Micrornas as functional mediators and biomarkers of bone metastasis
US9868992B2 (en) 2013-03-15 2018-01-16 Baylor Research Institute Tissue and blood-based miRNA biomarkers for the diagnosis, prognosis and metastasis-predictive potential in colorectal cancer
KR20150043937A (ko) 2013-10-15 2015-04-23 삼성전자주식회사 개체의 간암 진단용 조성물, 개체의 간암 진단하는 방법 및 개체의 간암 진단에 필요한 정보를 얻는 방법
KR101685107B1 (ko) * 2013-10-16 2016-12-09 서울대학교산학협력단 개체의 조직 또는 장기 손상 진단용 조성물 및 키트, 개체의 조직 또는 장기 손상을 예측 또는 진단하는 방법 및 치료제를 탐색하는 방법
CN103805603B (zh) * 2014-01-20 2016-01-20 南京医科大学附属南京儿童医院 与常见型先天肠管无神经节细胞症发生相关的血浆miRNA标志物及其应用
CN103740848B (zh) * 2014-01-28 2015-10-28 厦门大学附属中山医院 基于AllGlo探针荧光定量PCR的hsa-miR-146检测试剂盒及其检测方法
US10632349B2 (en) 2017-11-03 2020-04-28 Parsons Xtreme Golf, LLC Golf club heads and methods to manufacture golf club heads
WO2015153679A1 (en) 2014-03-31 2015-10-08 H. Lee Moffitt Cancer Center And Research Institute, Inc. Microrna assay for detection and management of pancreatic cancer precursors
US9631194B2 (en) 2014-04-04 2017-04-25 Beth Israel Deaconess Medical Center Methods and compositions for use in treatment of FOXP2-related cancers
CN103937888B (zh) * 2014-04-14 2016-08-17 上海交通大学 鉴别胃癌的血浆microRNA标志物的筛选与应用
ES2744186T3 (es) * 2014-04-25 2020-02-24 Childrens Medical Center Composiciones y métodos para tratar las hemoglobinopatías
EP3444362B1 (en) * 2014-05-02 2020-12-09 Ruprecht-Karls-Universität Heidelberg Circulating mirnas as early detection marker and prognostic marker
CN111996254B (zh) 2014-06-12 2024-10-18 东丽株式会社 前列腺癌的检测试剂盒或装置以及检测方法
ES2481819B1 (es) * 2014-06-12 2015-04-01 Sistemas Genómicos, S.L. Método de evaluación para evaluar una posibilidad de cáncer de mama
KR102401222B1 (ko) 2014-06-13 2022-05-24 국립연구개발법인 고쿠리츠간켄큐센터 유방암 검출 키트 또는 디바이스 및 검출 방법
KR102633955B1 (ko) * 2014-06-13 2024-02-06 도레이 카부시키가이샤 대장암의 검출 키트 또는 디바이스 및 검출 방법
US10597727B2 (en) 2014-06-16 2020-03-24 Toray Industries, Inc. Stomach cancer detection kit or device, and detection method
JP5795115B1 (ja) * 2014-06-19 2015-10-14 アイリスオーヤマ株式会社 Ｌｅｄ照明装置
US9623040B2 (en) 2014-07-14 2017-04-18 The Board Of Trustees Of The Leland Stanford Junior University Immunomodulation by controlling expression levels of microRNAs in dendritic cells
KR102237960B1 (ko) * 2014-08-07 2021-04-08 에이전시 포 사이언스, 테크놀로지 앤드 리서치 위암 진단용 microrna 바이오마커
CN104293923A (zh) * 2014-09-19 2015-01-21 浙江大学 荧光定量PCR检测组织中miR-100含量的试剂盒及其应用
US10570457B2 (en) 2014-09-26 2020-02-25 Medical Prognosis Institute A/S Methods for predicting drug responsiveness
US10370432B2 (en) 2014-10-03 2019-08-06 University Of Massachusetts Heterologous targeting peptide grafted AAVS
EP3200830B1 (en) 2014-10-03 2020-09-09 University of Massachusetts High efficiency library-identified aav vectors
RU2020140209A (ru) 2014-10-21 2021-01-25 Юниверсити Оф Массачусетс Варианты рекомбинантных aav и их применения
WO2016077125A1 (en) 2014-11-10 2016-05-19 Moderna Therapeutics, Inc. Alternative nucleic acid molecules containing reduced uracil content and uses thereof
CN104491880A (zh) * 2014-12-31 2015-04-08 中国人民解放军第三军医大学 MicroRNA-141作为抑制剂的用途
TWI626314B (zh) * 2015-01-09 2018-06-11 長庚大學 評估罹患大腸直腸癌風險的方法
TWI571514B (zh) * 2015-01-09 2017-02-21 長庚大學 評估罹患大腸直腸癌風險的方法
WO2016131009A1 (en) 2015-02-13 2016-08-18 University Of Massachusetts Compositions and methods for transient delivery of nucleases
EP3919625A1 (en) * 2015-02-24 2021-12-08 Theoria Science Inc. Method for diagnosing brain metastasis
US10487324B2 (en) * 2015-02-25 2019-11-26 Washington University Methods to detect motor neuron disease comprising micro-RNAs
JP6548184B2 (ja) * 2015-02-27 2019-07-24 国立大学法人北海道大学 がんの悪性度、予後及び／又は抗がん剤治療の有効性を判定するためのバイオマーカー、抗がん剤を選択するためのコンパニオン診断薬並びに抗がん剤
US11046955B2 (en) 2015-04-24 2021-06-29 University Of Massachusetts Modified AAV constructs and uses thereof
CN105497900A (zh) * 2015-04-30 2016-04-20 苏州大学 一种抗未分化甲状腺癌耐药靶点及其应用
CN107921147B (zh) * 2015-05-05 2021-12-24 江苏命码生物科技有限公司 一种新的前体miRNA及其在肿瘤治疗中的应用
WO2016197024A2 (en) 2015-06-05 2016-12-08 MiRagen Therapeutics, Inc. Mir-155 inhibitors for treating cutaneous t cell lymphoma (ctcl)
KR101814868B1 (ko) 2015-06-18 2018-01-04 재단법인대구경북과학기술원 마이크로 rna와 nmda 수용체의 상관관계를 이용한 해마의 기능감소 판단 방법, 기능감소 억제 방법 및 기능감소 억제제 스크리닝 방법
EP3364996B1 (en) 2015-10-22 2021-08-25 University of Massachusetts Prostate-targeting adeno-associated virus serotype vectors
WO2017070525A1 (en) 2015-10-22 2017-04-27 University Of Massachusetts Methods and compositions for treating metabolic imbalance in neurodegenerative disease
CN105238863A (zh) * 2015-10-29 2016-01-13 中国科学院近代物理研究所 miR-197在作为肝癌检测标志物中的应用
CN105219867B (zh) * 2015-11-02 2016-08-17 北京博奥医学检验所有限公司 用于胃癌诊断的miRNA生物标志物及检测试剂盒
KR102601499B1 (ko) * 2015-11-06 2023-11-13 연세대학교 산학협력단 miRNA 발현 수준으로부터 UQCRB 관련 질병을 진단하는 방법
CN105441448B (zh) * 2015-11-26 2018-05-22 中国农业科学院北京畜牧兽医研究所 miR-192对绵羊骨骼肌卫星细胞增殖分化调控应用
CN105586401A (zh) * 2015-12-14 2016-05-18 常州杰傲医学检验所有限公司 一种用于乳腺癌诊断的miRNA标志物、其应用及诊断试剂盒
EP3390659A1 (en) * 2015-12-15 2018-10-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing or prognosing prostate cancer
EP3405579A1 (en) 2016-01-22 2018-11-28 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
WO2017136536A1 (en) 2016-02-02 2017-08-10 University Of Massachusetts Method to enhance the efficiency of systemic aav gene delivery to the central nervous system
WO2017139643A1 (en) 2016-02-12 2017-08-17 University Of Massachusetts Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
JP6670119B2 (ja) 2016-02-15 2020-03-18 Ｋｙｂ株式会社 ベーンポンプ
US10767178B2 (en) * 2016-02-26 2020-09-08 Yale University Compositions and methods of using piRNAS in cancer diagnostics and therapeutics
DK3426781T3 (da) 2016-03-07 2024-09-30 Us Health Mikro-rna'er og fremgangsmåder til anvendelse deraf
CN105755123A (zh) * 2016-03-21 2016-07-13 河北医科大学第医院 一种结直肠癌相关的标志物、其引物及应用
WO2017176929A1 (en) 2016-04-05 2017-10-12 University Of Massachusetts Compositions and methods for selective inhibition of grainyhead-like protein expression
EP3443001B1 (en) 2016-04-11 2025-04-30 Obsidian Therapeutics, Inc. REGULATED BIOCIRCUIT SYSTEMS
WO2017181105A1 (en) 2016-04-15 2017-10-19 University Of Massachusetts Methods and compositions for treating metabolic imbalance
DK3458083T5 (da) 2016-05-18 2024-10-21 Modernatx Inc Polynukleotider, der koder for interleukin-12 (il12), og anvendelser heraf
US10202604B2 (en) * 2016-05-26 2019-02-12 Stemirna Therapeutics Co., Ltd. Methods of using microRNA-141
WO2017218704A1 (en) 2016-06-14 2017-12-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
US11882815B2 (en) 2016-06-15 2024-01-30 University Of Massachusetts Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells
US11564997B2 (en) 2016-06-29 2023-01-31 Crispr Therapeutics Ag Materials and methods for treatment of friedreich ataxia and other related disorders
WO2018002812A1 (en) 2016-06-29 2018-01-04 Crispr Therapeutics Ag Materials and methods for treatment of myotonic dystrophy type 1 (dm1) and other related disorders
US11174469B2 (en) 2016-06-29 2021-11-16 Crispr Therapeutics Ag Materials and methods for treatment of Amyotrophic Lateral Sclerosis (ALS) and other related disorders
CA3029132A1 (en) 2016-07-06 2018-01-11 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of pain related disorders
US11459587B2 (en) 2016-07-06 2022-10-04 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of pain related disorders
US10801025B2 (en) 2016-07-26 2020-10-13 Indiana University Research And Technology Corporation MicroRNA therapy for pancreatic cancer
CN106244679B (zh) * 2016-07-27 2019-11-22 中国医学科学院基础医学研究所 miR-100抑制剂在降低癌症转移中的用途
CN106237344A (zh) * 2016-08-04 2016-12-21 北京信生元生物医学科技有限公司 miR‑1255在制备治疗膀胱癌药物中的应用
US11414708B2 (en) 2016-08-24 2022-08-16 Decipher Biosciences, Inc. Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
US10457940B2 (en) 2016-09-22 2019-10-29 University Of Massachusetts AAV treatment of Huntington's disease
CN106381298A (zh) * 2016-09-27 2017-02-08 和泓（厦门）生物技术有限公司 一种rna抑制剂及其应用
US9725769B1 (en) 2016-10-07 2017-08-08 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
CA3040483A1 (en) 2016-10-13 2018-04-19 University Of Massachusetts Aav capsid designs
EP3532070A1 (en) 2016-10-26 2019-09-04 Modernatx, Inc. Messenger ribonucleic acids for enhancing immune responses and methods of use thereof
US11584932B2 (en) 2016-11-01 2023-02-21 The Research Foundation For The State University Of New York 5-halouracil-modified microRNAs and their use in the treatment of cancer
US11583504B2 (en) 2016-11-08 2023-02-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
AU2017258901A1 (en) 2016-12-30 2018-07-19 Allarity Therapeutics Europe ApS Methods for predicting drug responsiveness in cancer patients
AU2018210695B2 (en) 2017-01-20 2024-07-18 The University Of British Columbia Molecular subtyping, prognosis, and treatment of bladder cancer
EP3576780A1 (en) 2017-02-01 2019-12-11 Modernatx, Inc. Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
US20200216857A1 (en) 2017-02-22 2020-07-09 Crispr Therapeutics Ag Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders
EP3585807A1 (en) 2017-02-22 2020-01-01 CRISPR Therapeutics AG Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disorders
CN119351474A (zh) 2017-02-22 2025-01-24 克里斯珀医疗股份公司 用于基因编辑的组合物和方法
EP3585899A1 (en) 2017-02-22 2020-01-01 CRISPR Therapeutics AG Materials and methods for treatment of primary hyperoxaluria type 1 (ph1) and other alanine-glyoxylate aminotransferase (agxt) gene related conditions or disorders
EP3585898A1 (en) 2017-02-22 2020-01-01 CRISPR Therapeutics AG Materials and methods for treatment of spinocerebellar ataxia type 1 (sca1) and other spinocerebellar ataxia type 1 protein (atxn1) gene related conditions or disorders
WO2018165600A1 (en) 2017-03-09 2018-09-13 Genomedx Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
US12215388B2 (en) 2017-05-03 2025-02-04 Lee Moffitt Cancer Center and Research Institute, Inc. Theranostic tools for management of pancreatic cancer and its precursors
US11078542B2 (en) 2017-05-12 2021-08-03 Decipher Biosciences, Inc. Genetic signatures to predict prostate cancer metastasis and identify tumor aggressiveness
US20200131498A1 (en) 2017-06-14 2020-04-30 Modernatx, Inc. Polynucleotides encoding methylmalonyl-coa mutase
AU2018293544A1 (en) * 2017-06-29 2019-12-19 The University Of Sydney Cell-free microRNA signatures of pancreatic islet beta cell death
AU2018310987A1 (en) 2017-08-04 2020-02-27 Decipher Biosciences, Inc. Use of immune cell-specific gene expression for prognosis of prostate cancer and prediction of responsiveness to radiation therapy
WO2019046809A1 (en) 2017-08-31 2019-03-07 Modernatx, Inc. METHODS OF MANUFACTURING LIPID NANOPARTICLES
CN107746886B (zh) * 2017-09-11 2019-10-01 朱伟 一种与结直肠癌辅助诊断相关的血浆miRNA标志物及其应用
CN107488734B (zh) * 2017-10-10 2019-11-05 广州医科大学附属第二医院 miR-19a-3p在制备前列腺癌骨转移诊断试剂和治疗药物中的应用
CN107904301A (zh) * 2017-10-26 2018-04-13 宁波市微循环与莨菪类药研究所 miR‑181a作为海洛因成瘾的生物标记物及其在制备抗海洛因复吸药物中的应用
WO2019102381A1 (en) 2017-11-21 2019-05-31 Casebia Therapeutics Llp Materials and methods for treatment of autosomal dominant retinitis pigmentosa
CN107815492A (zh) * 2017-12-08 2018-03-20 武汉科技大学 一种基于qpcr诊断乳腺癌的检测方法
US20210079478A1 (en) * 2017-12-13 2021-03-18 Hiroshima University Method for assisting in detection of breast cancer
EP3728594A1 (en) 2017-12-21 2020-10-28 CRISPR Therapeutics AG Materials and methods for treatment of usher syndrome type 2a
EP3728595A1 (en) 2017-12-21 2020-10-28 CRISPR Therapeutics AG Materials and methods for treatment of usher syndrome type 2a and/or non-syndromic autosomal recessive retinitis pigmentosa (arrp)
CN107881239B (zh) * 2017-12-27 2021-04-13 广西壮族自治区肿瘤防治研究所 血浆中与结直肠癌转移相关的miRNA标志物及其应用
US20190314291A1 (en) 2018-01-30 2019-10-17 Modernatx, Inc. Compositions and methods for delivery of agents to immune cells
EP3773745A1 (en) 2018-04-11 2021-02-17 ModernaTX, Inc. Messenger rna comprising functional rna elements
CN108559773A (zh) * 2018-04-18 2018-09-21 江苏省人民医院（南京医科大学第附属医院） miR-218在制备治疗骨质疏松症药物中的应用
US20210071180A1 (en) * 2018-04-23 2021-03-11 Board Of Regents, The Universy Of Texas System Microrna 584-5p compositions and methods for treating cancer
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
US11535899B2 (en) 2018-08-10 2022-12-27 Toray Industries, Inc. Kit, device and method for detecting prostate cancer
WO2020061457A1 (en) 2018-09-20 2020-03-26 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
WO2020086742A1 (en) 2018-10-24 2020-04-30 Obsidian Therapeutics, Inc. Er tunable protein regulation
WO2020132494A2 (en) * 2018-12-21 2020-06-25 Baylor Research Institute Methods for prognosing, diagnosing, and treating gastric cancer
CN109971851A (zh) * 2019-01-22 2019-07-05 宁波大学 MiR-125b-2-3p作为鉴别诊断肾癌亚型的分子标志物及其在肿瘤转移中的用途
MX2021009245A (es) 2019-01-31 2021-11-12 Modernatx Inc Metodos de preparacion de nanoparticulas lipidicas.
CN109913454B (zh) * 2019-03-05 2021-08-10 上海珑欣生物医学科技有限公司 一种生物活性提高的microRNA及其应用
KR20210149251A (ko) 2019-03-08 2021-12-08 옵시디안 테라퓨틱스, 인크. 조율가능한 조절을 위한 인간 탄산 무수화효소 2 조성물 및 방법
WO2020227604A1 (en) * 2019-05-08 2020-11-12 Nova Southeastern University Regulation of nucleotide excision repair (ner) by microrna for treatment of breast cancer
KR20220024060A (ko) * 2019-06-19 2022-03-03 셀룰래리티 인코포레이티드 질환 치료용 엑소좀
US20220387628A1 (en) 2019-06-24 2022-12-08 Modernatx, Inc. Messenger rna comprising functional rna elements and uses thereof
WO2020263883A1 (en) 2019-06-24 2020-12-30 Modernatx, Inc. Endonuclease-resistant messenger rna and uses thereof
CN110354137B (zh) * 2019-08-20 2023-08-04 中山大学附属第六医院 miRNA-197-3p在制备抗前列腺癌药物中的应用
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
CN110791560B (zh) 2019-11-06 2021-09-14 中国医学科学院医药生物技术研究所 一种用于阿尔茨海默病诊断和/或治疗的miRNA标志物
CN116133652A (zh) 2020-01-31 2023-05-16 摩登纳特斯有限公司 制备脂质纳米粒子的方法
US20230070049A1 (en) * 2020-02-03 2023-03-09 Rutgers, The State University Of New Jersey Microrna-7 compositions for promoting functional recovery following spinal cord injury and methods of use thereof
CN111349704B (zh) * 2020-03-17 2020-11-24 河北医科大学第三医院 肝癌的诊断产品和治疗组合物
BR112022019889A2 (pt) 2020-04-02 2023-03-07 Mirecule Inc Inibição direcionada com o uso de oligonucleotídeos modificados geneticamente
CN111471683B (zh) * 2020-04-15 2021-09-07 湖南省科域生物医药科技有限公司 miR-93-5p作为诊断和治疗胃癌标志物的应用
CN111575374B (zh) * 2020-04-29 2023-06-27 大连凯伦生物科技咨询有限公司 用于早期胰腺肿瘤检测分子标志物、其检测方法及应用
US20230407401A1 (en) * 2020-05-29 2023-12-21 National Institute Of Immunology Dna damage dependent microrna signature for cancers, methods and uses related thereto
CN111500739B (zh) * 2020-06-15 2022-05-17 南通大学附属医院 一种用于检测鼻咽癌预后的生物标志物及其应用
WO2021262919A2 (en) 2020-06-26 2021-12-30 The Research Foundation For The State University Of New York 5-halouracil-modified micrornas and their use in the treatment of cancer
CN112048554A (zh) * 2020-06-29 2020-12-08 浙江大学 脂质体纳米颗粒芯片及其在制备胰腺癌诊断产品中的应用和相应标志物
CN116710079A (zh) 2020-07-24 2023-09-05 斯特兰德生物科技公司 包含经修饰的核苷酸的脂质纳米颗粒
CN111944809B (zh) * 2020-07-28 2022-07-29 武汉睿健医药科技有限公司 帕金森病的诊断标志物及其应用
TW202220637A (zh) 2020-08-06 2022-06-01 美商現代公司 製備脂質奈米顆粒之方法
CN112138161B (zh) * 2020-08-28 2022-01-14 中国人民解放军总医院 一种抑制剂的用途以及一种药物的用途
CN112226514B (zh) * 2020-11-23 2021-08-03 苏州京脉生物科技有限公司 用于早期胃癌检测的标志物组合、试剂盒及其应用
EP4012047A1 (en) * 2020-12-11 2022-06-15 Fondazione di Religione e di Culto "Casa Sollievo Della Sofferenza" - Opera di San Pio da Pietrelcina Prognostic method for aggressive lung adenocarcinomas
CN112575088B (zh) * 2020-12-29 2022-07-05 浙江大学医学院附属妇产科医院 一种血浆外泌体miRNA生物标记物及其应用
AU2022205679A1 (en) 2021-01-08 2023-07-06 Strand Therapeutics Inc. Expression constructs and uses thereof
KR102548285B1 (ko) * 2021-02-10 2023-06-28 영남대학교 산학협력단 특발성 신증후군 진단용 바이오마커 조성물 및 이의 용도
EP4334446A1 (en) 2021-05-03 2024-03-13 CureVac SE Improved nucleic acid sequence for cell type specific expression
CN113322237B (zh) * 2021-06-16 2022-05-13 中国医学科学院肿瘤医院 一种vav2基因缺失的肿瘤细胞系
CN114081896B (zh) * 2021-11-22 2023-03-14 新乡医学院 let-7i-3p在制备治疗结直肠癌的药物中的应用及方法
US12037616B2 (en) 2022-03-01 2024-07-16 Crispr Therapeutics Ag Methods and compositions for treating angiopoietin-like 3 (ANGPTL3) related conditions
AR128976A1 (es) 2022-03-11 2024-07-03 Consejo Nacional De Investigaciones Cientificas Y Tecn Conicet Diagnóstico y tratamiento de cáncer de mama
EP4501338A4 (en) 2022-03-28 2026-03-11 Hiroko Science Inc Pharmaceutical composition containing MIR-140 and its manufacturing process
IL316186A (en) 2022-04-26 2024-12-01 Strand Therapeutics Inc Lipid nanoparticles containing Venezuelan equine encephalitis (VEE) replicon and uses thereof
CN115044676B (zh) * 2022-06-17 2025-08-26 连云港市第一人民医院 外泌体miRNA在预测非小细胞肺癌患者免疫治疗效果中的应用
WO2024026487A1 (en) 2022-07-29 2024-02-01 Modernatx, Inc. Lipid nanoparticle compositions comprising phospholipid derivatives and related uses
WO2024026475A1 (en) 2022-07-29 2024-02-01 Modernatx, Inc. Compositions for delivery to hematopoietic stem and progenitor cells (hspcs) and related uses
EP4561546A1 (en) 2022-07-29 2025-06-04 ModernaTX, Inc. Lipid nanoparticle compositions comprising surface lipid derivatives and related uses
KR20260006623A (ko) 2023-04-28 2026-01-13 센젠 센신 바이오테크놀로지 컴퍼니 리미티드 변형된 전달 담체 및 이의 용도
WO2024259373A1 (en) 2023-06-14 2024-12-19 Modernatx, Inc. Compounds and compositions for delivery of therapeutic agents
WO2025160381A1 (en) 2024-01-26 2025-07-31 Modernatx, Inc. Methods of preparing lipid nanoparticles
WO2025166202A1 (en) 2024-01-31 2025-08-07 Modernatx, Inc. Lipid nanoparticle compositions comprising sialic acid derivatives and the uses thereof
ES3048857A1 (es) * 2024-06-10 2025-12-11 Fundacion Para La Investig E Innovacion Biosanitaria Del Principado De Asturias Finba FIRMA DE miRNA UTILES EN LA DISCRIMINACION DE TUMORES
CN120643588B (zh) * 2025-08-13 2025-10-24 四川大学华西医院 miR-30d-5p与CYP24A1抑制物在激素性股骨头坏死中的应用

Family Cites Families (235)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4172124A (en) 1978-04-28 1979-10-23 The Wistar Institute Method of producing tumor antibodies
US4608337A (en) 1980-11-07 1986-08-26 The Wistar Institute Human hybridomas and the production of human monoclonal antibodies by human hybridomas
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4701409A (en) 1984-11-15 1987-10-20 The Wistar Institute Detection of B-cell neoplasms
US4693975A (en) 1984-11-20 1987-09-15 The Wistar Institute Human hybridroma fusion partner for production of human monoclonal antibodies
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5015568A (en) 1986-07-09 1991-05-14 The Wistar Institute Diagnostic methods for detecting lymphomas in humans
US5202429A (en) 1986-07-09 1993-04-13 The Wistar Institute DNA molecules having human BCL-2 gene sequences
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
ATE120497T1 (de) 1988-05-09 1995-04-15 Univ Temple Verfahren zur voraussage der wirksamkeit einer antineoplastichen behandlung bei einzelnen patienten.
US5198338A (en) 1989-05-31 1993-03-30 Temple University Molecular probing for human t-cell leukemia and lymphoma
US5149628A (en) 1989-11-15 1992-09-22 Temple University Methods for detecting bcl-3 gene in human leukemias
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
WO1993012136A1 (en) 1991-12-11 1993-06-24 Thomas Jefferson University Detection and treatment of acute leukemias resulting from chromosome abnormalities in the all-1 region
US6040140A (en) 1991-12-11 2000-03-21 Thomas Jefferson University Methods for screening and treating leukemias resulting from all-1 region chromosome abnormalities
US5633135A (en) 1991-12-11 1997-05-27 Thomas Jefferson University Chimeric nucleic acids and proteins resulting from ALL-1 region chromosome abnormalities
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
US5674682A (en) 1992-10-29 1997-10-07 Thomas Jefferson University Nucleic acid primers for detecting micrometastasis of prostate cancer
PT667920E (pt) 1992-10-29 2003-06-30 Univ Jefferson Metodos de deteccao de micrometasteses do cancro da prostata
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US7175995B1 (en) 1994-10-27 2007-02-13 Thomas Jefferson University TCL-1 protein and related methods
US5985598A (en) 1994-10-27 1999-11-16 Thomas Jefferson University TCL-1 gene and protein and related methods and compositions
US5695944A (en) 1995-05-05 1997-12-09 Thomas Jefferson University Modulation of bcl-2 phosphorylation
US5567586A (en) 1995-05-18 1996-10-22 Thomas Jefferson University Methods of indentifying solid tumors with chromosome abnormalities in the ALL-1 region
US5928884A (en) 1996-02-09 1999-07-27 Croce; Carlo M. FHIT proteins and nucleic acids and methods based thereon
US6242212B1 (en) 1996-02-09 2001-06-05 Thomas Jefferson University Fragile histidine triad (FHIT) nucleic acids and methods of producing FHIT proteins
US5849902A (en) 1996-09-26 1998-12-15 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
US6187536B1 (en) * 1997-02-18 2001-02-13 Thomas Jefferson University Methods of identifying and detecting pancreatic cancer
WO1998045480A1 (en) 1997-04-04 1998-10-15 The Texas A & M University System Noninvasive detection of colonic biomarkers using fecal messenger rna
US6303323B1 (en) 1997-10-21 2001-10-16 Cancer Research Campaign Technology Limited Detection of dysplastic or neoplastic cells using anti-MCM5 antibodies
GB2332515B (en) 1997-10-21 1999-12-15 Cancer Res Campaign Tech Determination of cellular growth abnormality
WO2000003685A2 (en) 1998-07-20 2000-01-27 Thomas Jefferson University Nitrilase homologs
AU5128999A (en) 1998-07-24 2000-02-14 Yeda Research And Development Co. Ltd. Prevention of metastasis with 5-aza-2'-deoxycytidine
WO2000046364A1 (en) 1999-02-05 2000-08-10 The Uab Research Foundation Fiber receptor-independent system for the propagation of adenoviral vectors
US7141417B1 (en) 1999-02-25 2006-11-28 Thomas Jefferson University Compositions, kits, and methods relating to the human FEZ1 gene, a novel tumor suppressor gene
CA2367906A1 (en) 1999-03-15 2000-09-21 Thomas Jefferson University Tcl-1b gene and protein and related methods and compositions
AU6227400A (en) 1999-07-26 2001-02-13 Childrens Hospital Los Angeles Research Institute Fenretinide increases antibody cellular toxicity
US7163801B2 (en) 1999-09-01 2007-01-16 The Burnham Institute Methods for determining the prognosis for cancer patients using tucan
US20030206958A1 (en) 2000-12-22 2003-11-06 Cattaneo Maurizio V. Chitosan biopolymer for the topical delivery of active agents
US6891031B2 (en) * 2000-02-18 2005-05-10 The Regents Of The University Of California Coordinate cytokine regulatory sequences
WO2001068666A1 (en) 2000-03-14 2001-09-20 Thomas Jefferson University Tcl1 enhances akt kinase activity and mediates its nuclear translocation
ATE450621T2 (de) 2000-03-30 2009-12-15 Whitehead Biomedical Inst Mediatoren von rns-interferenz, die rns- sequenzspezifisch sind
EP1276879A4 (en) 2000-04-11 2004-12-22 Univ Jefferson MUIR-TORRE-LIKE SYNDROME IN Fhit-DEFECTIVE MICE
US20020086331A1 (en) 2000-05-16 2002-07-04 Carlo Croce Crystal structure of worm NitFhit reveals that a Nit tetramer binds two Fhit dimers
US7060811B2 (en) 2000-10-13 2006-06-13 Board Of Regents, The University Of Texas System WWOX: a tumor suppressor gene mutated in multiple cancers
US20020173478A1 (en) 2000-11-14 2002-11-21 The Trustees Of The University Of Pennsylvania Post-transcriptional gene silencing by RNAi in mammalian cells
US20040033502A1 (en) 2001-03-28 2004-02-19 Amanda Williams Gene expression profiles in esophageal tissue
US20050176025A1 (en) 2001-05-18 2005-08-11 Sirna Therapeutics, Inc. RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA)
WO2003070969A2 (en) 2002-02-20 2003-08-28 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF BCL2 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
CA2462144C (en) 2001-09-28 2016-09-20 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Micro-rna molecules
US7371736B2 (en) 2001-11-07 2008-05-13 The Board Of Trustees Of The University Of Arkansas Gene expression profiling based identification of DKK1 as a potential therapeutic targets for controlling bone loss
AU2002360377A1 (en) 2001-11-09 2003-05-19 The Ohio State University Research Foundation Baalc expression as a diagnostic marker for acute leukemia
GB0128898D0 (en) 2001-12-03 2002-01-23 Biotech Res Ventures Pte Ltd Materials and methods relating to the stabilization and activation of a tumour suppressor protein
WO2003069853A1 (en) 2002-02-12 2003-08-21 Nokia Corporation Method for controlling data transmission, and data transmission system
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US7799827B2 (en) 2002-03-08 2010-09-21 Eisai Co., Ltd. Macrocyclic compounds useful as pharmaceuticals
DK2258872T3 (da) * 2002-03-13 2013-11-18 Genomic Health Inc Genekspressionsprofilering i biopsier af tumorvæv
CN1649613A (zh) 2002-04-08 2005-08-03 赛弗根生物系统股份有限公司 肝细胞癌血清生物标记
EP1499182B1 (en) 2002-04-29 2009-10-28 Thomas Jefferson University Human chronic lymphocytic leukemia modeled in mouse by targeted tcl1 expression
CA2486658C (en) 2002-05-31 2014-07-29 The Regents Of The University Of California Method for efficient rna interference in mammalian cells
JP2005528115A (ja) 2002-05-31 2005-09-22 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ 幹細胞および癌幹細胞を同定および単離する方法
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
US20050260639A1 (en) 2002-09-30 2005-11-24 Oncotherapy Science, Inc. Method for diagnosing pancreatic cancer
US20050266443A1 (en) 2002-10-11 2005-12-01 Thomas Jefferson University Novel tumor suppressor gene and compositions and methods for making and using the same
CA2501602A1 (en) 2002-10-11 2004-04-22 Thomas Jefferson University Novel tumor suppressor gene and compositions and methods for making and using the same
JP4939055B2 (ja) 2002-11-13 2012-05-23 トマス ジェファソン ユニバーシティ 癌の診断および治療のための組成物および方法
CN1719973A (zh) 2002-11-13 2006-01-11 托马斯杰斐逊大学 用于癌症诊断和治疗的组合物和方法
US7250496B2 (en) 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
US20040102421A1 (en) 2002-11-21 2004-05-27 Children's Hospital Research Center At Oakland Tocopherol and tocotrienol anti-inflammatory medicaments
WO2004071464A2 (en) * 2003-02-12 2004-08-26 Johns Hopkins University School Of Medicine Diagnostic application of differentially-expressed genes in lympho-hematopoietic stem cells
WO2004079013A1 (en) 2003-03-03 2004-09-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer
US7183384B2 (en) 2003-03-06 2007-02-27 A & G Pharmaceutical, Inc. Monoclonal antibody 7H11 reactive with human cancer
WO2004081196A2 (en) 2003-03-11 2004-09-23 Qlt Usa Inc. Formulations for cell- schedule dependent anticancer agents
AU2003286741A1 (en) 2003-05-02 2004-11-26 Thomas Jefferson University Methods and compositions for diagnosis and therapy of parkin-associated disorders
WO2006031210A1 (en) 2003-05-29 2006-03-23 Board Of Regents, The University Of Texas Systems Jabi as a prognostic marker and a therapeutic target for human cancer
WO2005047458A2 (en) 2003-06-18 2005-05-26 Genelux Corporation Modified recombinant vaccina viruses and other microorganisms, uses thereof
EP2530157B1 (en) * 2003-07-31 2016-09-28 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of miRNAs
US8106180B2 (en) * 2003-08-07 2012-01-31 Whitehead Institute For Biomedical Research Methods and products for expression of micro RNAs
US20050037362A1 (en) 2003-08-11 2005-02-17 Eppendorf Array Technologies, S.A. Detection and quantification of siRNA on microarrays
US8412541B2 (en) 2003-08-14 2013-04-02 Edda Technology, Inc. Method and system for intelligent qualitative and quantitative analysis for medical diagnosis
US20050084883A1 (en) 2003-08-25 2005-04-21 The Johns Hopkins University School Of Medicine Method of diagnosis and treatment of pancreatic endocrine neoplasms based on differential gene expression analysis
JPWO2005028648A1 (ja) 2003-09-22 2007-11-15 愛知県 リンパ腫の病型および予後診断方法
WO2005031002A2 (en) 2003-09-22 2005-04-07 Rosetta Inpharmatics Llc Synthetic lethal screen using rna interference
CN1890382A (zh) 2003-09-24 2007-01-03 肿瘤疗法科学股份有限公司 检测、诊断和治疗肝细胞癌(hcc)的方法
US20050186589A1 (en) 2003-11-07 2005-08-25 University Of Massachusetts Interspersed repetitive element RNAs as substrates, inhibitors and delivery vehicles for RNAi
US20050164252A1 (en) * 2003-12-04 2005-07-28 Yeung Wah Hin A. Methods using non-genic sequences for the detection, modification and treatment of any disease or improvement of functions of a cell
EP1709193B1 (en) 2003-12-19 2011-03-16 The Regents of The University of California Methods and materials for assessing prostate cancer therapies
JP4120002B2 (ja) 2004-01-07 2008-07-16 愛知県 ｍｉＲＮＡを用いた癌の予後判定方法、癌の遺伝子治療ベクター及び癌治療用医薬組成物
US20050256072A1 (en) 2004-02-09 2005-11-17 University Of Massachusetts Dual functional oligonucleotides for use in repressing mutant gene expression
CA2554818A1 (en) * 2004-02-09 2005-08-25 Thomas Jefferson University Diagnosis and treatment of cancers with microrna located in or near cancer-associated chromosomal features
AU2005214904B2 (en) 2004-02-13 2011-07-21 Rockefeller University Anti-microRNA oligonucleotide molecules
CA2558366A1 (en) 2004-02-23 2005-09-01 Erasmus Universiteit Rotterdam Classification, diagnosis and prognosis of acute myeloid leukemia by gene expression profiling
WO2005094263A2 (en) 2004-03-23 2005-10-13 Pintex Pharmaceuticals, Inc. Methods of determining the prognosis and treatment of subjects with colon cancer
US20060134639A1 (en) 2004-04-06 2006-06-22 Huffel Christophe V Method for the determination of cellular transcriptional regulation
US7365058B2 (en) 2004-04-13 2008-04-29 The Rockefeller University MicroRNA and methods for inhibiting same
CN101056991A (zh) 2004-04-20 2007-10-17 基因耐克生物医学制品有限公司 检测ncRNA的方法
WO2005111211A2 (en) * 2004-05-14 2005-11-24 Rosetta Genomics Ltd. Micronas and uses thereof
EP2290073A3 (en) 2004-05-28 2011-08-31 Asuragen, Inc. Methods and compositions involving microRNA
US7635563B2 (en) 2004-06-30 2009-12-22 Massachusetts Institute Of Technology High throughput methods relating to microRNA expression analysis
WO2006007529A2 (en) 2004-07-01 2006-01-19 University Of Pittsburgh Of The Commonwealth System For Higher Education Immunosuppressive exosomes
US20060037088A1 (en) 2004-08-13 2006-02-16 Shulin Li Gene expression levels as predictors of chemoradiation response of cancer
EP2338994B1 (en) 2004-09-02 2014-03-19 Yale University Regulation of oncogenes by microRNAs
US7642348B2 (en) * 2004-10-04 2010-01-05 Rosetta Genomics Ltd Prostate cancer-related nucleic acids
US7592441B2 (en) 2004-10-04 2009-09-22 Rosetta Genomics Ltd Liver cancer-related nucleic acids
FR2877350B1 (fr) 2004-11-03 2010-08-27 Centre Nat Rech Scient IDENTIFICATION ET UTILISATION DE miRNAs IMPLIQUES DANS LA DIFFERENCIATION DE CELLULES ISSUES D'UNE LEUCEMIE MYELOIDE
CA2857878A1 (en) 2004-11-12 2006-12-28 Asuragen, Inc. Methods and compositions involving mirna and mirna inhibitor molecules
EP1662259A1 (en) 2004-11-25 2006-05-31 Cellzome Ag Use of Eph receptor inhibitors for the treatment of neurodegenerative diseases
WO2006066158A2 (en) 2004-12-14 2006-06-22 Alnylam Pharmaceuticals, Inc. Rnai modulation of mll-af4 and uses thereof
US20060185027A1 (en) 2004-12-23 2006-08-17 David Bartel Systems and methods for identifying miRNA targets and for altering miRNA and target expression
US20070099196A1 (en) 2004-12-29 2007-05-03 Sakari Kauppinen Novel oligonucleotide compositions and probe sequences useful for detection and analysis of micrornas and their target mRNAs
JP2008528003A (ja) 2005-01-25 2008-07-31 ロゼッタ インファーマティックス エルエルシー 小ｒｎａ分子の定量方法
US8071306B2 (en) 2005-01-25 2011-12-06 Merck Sharp & Dohme Corp. Methods for quantitating small RNA molecules
EP1856286A2 (en) 2005-02-11 2007-11-21 Wisconsin Alumni Research Foundation Mir-155 assay
KR101253576B1 (ko) 2005-02-23 2013-04-11 제넨테크, 인크. Ｈｅｒ 이량체화 억제제를 이용한 암 환자에서의 질환진행까지의 시간 또는 생존의 연장
US20070065840A1 (en) 2005-03-23 2007-03-22 Irena Naguibneva Novel oligonucleotide compositions and probe sequences useful for detection and analysis of microRNAS and their target mRNAS
GB2425311A (en) 2005-04-15 2006-10-25 Ist Superiore Sanita Micro RNA against kit protein
AU2006242225B2 (en) 2005-04-29 2012-01-12 Rockefeller University Human microRNAs and methods for inhibiting same
EP1880027B1 (en) 2005-05-02 2014-02-19 Cold Spring Harbor Laboratory Composition and methods for cancer diagnosis utilizing the mir 17-92 cluster
WO2006133022A2 (en) 2005-06-03 2006-12-14 The Johns Hopkins University Compositions and methods for decreasing microrna expression for the treatment of neoplasia
US20070065844A1 (en) 2005-06-08 2007-03-22 Massachusetts Institute Of Technology Solution-based methods for RNA expression profiling
US20060292616A1 (en) 2005-06-23 2006-12-28 U.S. Genomics, Inc. Single molecule miRNA-based disease diagnostic methods
CN103820562B (zh) * 2005-08-01 2015-05-13 俄亥俄州立大学研究基金会 用于乳腺癌的诊断、预后和治疗的基于MicroRNA的方法和组合物
US20070213292A1 (en) 2005-08-10 2007-09-13 The Rockefeller University Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
EP1919512B1 (en) 2005-08-10 2014-11-12 Alnylam Pharmaceuticals Inc. Chemically modified oligonucleotides for use in modulating micro rna and uses thereof
CA2621441C (en) 2005-09-12 2014-05-20 The Ohio State University Research Foundation Compositions and methods for the diagnosis and therapy of bcl2-associated cancers
WO2007031091A2 (en) 2005-09-15 2007-03-22 Santaris Pharma A/S Rna antagonist compounds for the modulation of p21 ras expression
US20090270484A1 (en) 2005-10-05 2009-10-29 The Ohio State University Research Foundation WWOX Vectors and Uses in Treatment of Cancer
US20070092882A1 (en) 2005-10-21 2007-04-26 Hui Wang Analysis of microRNA
US8445198B2 (en) 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
US7390792B2 (en) 2005-12-15 2008-06-24 Board Of Regents, The University Of Texas System MicroRNA1 therapies
EP1966390A1 (en) 2005-12-29 2008-09-10 Exiqon A/S Detection of tissue origin of cancer
CN101384273B (zh) 2006-01-05 2013-07-10 俄亥俄州立大学研究基金会 胰腺内分泌和腺泡肿瘤中的微小rna表达异常
EP2502630B1 (en) 2006-01-05 2015-03-11 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
EP2484782B1 (en) * 2006-01-05 2015-11-18 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers
WO2008051260A1 (en) 2006-01-13 2008-05-02 Battelle Memorial Institute Methods for assessing copd-retlated diseases
EP2369013A1 (en) 2006-03-20 2011-09-28 The Ohio State University Research Foundation Micro-RNA fingerprints during human megakaryocytopoiesis
WO2007112097A2 (en) 2006-03-24 2007-10-04 Children's Medical Center Corporation Novel signature self renewal gene expression programs
WO2007115134A2 (en) 2006-03-29 2007-10-11 Wayne State University Liposomal nanoparticles and other formulations of fenretinide for use in therapy and drug delivery
DK2666859T3 (en) 2006-04-03 2019-04-08 Roche Innovation Ct Copenhagen As PHARMACEUTICAL COMPOSITION CONTAINING ANTI-miRNA ANTISENSE OLIGONUCLEOTIDES
CA2650026C (en) 2006-04-24 2013-01-22 The Ohio State University Research Foundation Pre-b cell proliferation and lymphoblastic leukemia/high-grade lymphoma in mir155 transgenic mice
WO2008002672A2 (en) 2006-06-28 2008-01-03 The Cleveland Clinic Foundation Targets for use in diagnosis, prognosis and therapy of cancer
US9115389B2 (en) 2006-06-30 2015-08-25 Rosetta Genomics Ltd. Method for detecting a target nucleic acid comprising two portions using probes having a first portion complementary to the first portion of the target nucleic acid and a second portion substantially complementary to the second portion of the target nucleic acid
EP2455493B1 (en) 2006-07-13 2014-01-08 The Ohio State University Research Foundation Micro-RNA-based methods and compositions for the diagnosis and treatment of colon related diseases
SG174107A1 (en) 2006-08-30 2011-09-29 Univ Michigan New small molecule inhibitors of mdm2 and the uses thereof
US20080193943A1 (en) 2006-09-05 2008-08-14 Abbott Laboratories Companion diagnostic assays for cancer therapy
CA2663878A1 (en) 2006-09-19 2008-03-27 Asuragen, Inc. Mir-200 regulated genes and pathways as targets for therapeutic intervention
JP2010510964A (ja) 2006-09-19 2010-04-08 アシュラジェン インコーポレイテッド 治療的介入の標的としての、ｍｉＲ−１５、ｍｉＲ−２６、ｍｉＲ−３１、ｍｉＲ−１４５、ｍｉＲ−１４７、ｍｉＲ−１８８、ｍｉＲ−２１５、ｍｉＲ−２１６、ｍｉＲ−３３１、ｍｍｕ−ｍｉＲ−２９２−３ｐによって調節される遺伝子および経路
CA2663027A1 (en) 2006-09-19 2008-08-14 The Ohio State University Research Foundation Tcl1 expression in chronic lymphocytic leukemia (cll) regulated by mir-29 and mir-181
WO2008036765A2 (en) 2006-09-19 2008-03-27 Asuragen, Inc. Micrornas differentially expressed in pancreatic diseases and uses thereof
JP2008086201A (ja) 2006-09-29 2008-04-17 Gifu Prefecture Kenkyu Kaihatsu Zaidan マイクロｒｎａ生成の検出方法と癌の診断・治療およびマイクロｒｎａ生成調整剤
US8202968B2 (en) 2006-10-20 2012-06-19 Washington University Predicting lung cancer survival using gene expression
US8252538B2 (en) 2006-11-01 2012-08-28 The Ohio State University MicroRNA expression signature for predicting survival and metastases in hepatocellular carcinoma
CN101316935B (zh) 2006-11-28 2012-02-29 博奥生物有限公司 一种用于诊断食道癌的芯片
US8293684B2 (en) 2006-11-29 2012-10-23 Exiqon Locked nucleic acid reagents for labelling nucleic acids
WO2008070082A2 (en) 2006-12-04 2008-06-12 The Johns Hopkins University Stem-progenitor cell specific micro-ribonucleic acids and uses thereof
GB0624302D0 (en) 2006-12-05 2007-01-17 Istituto Superiore Di Sanito Micro RNA
CA2671299A1 (en) 2006-12-08 2008-06-19 Asuragen, Inc. Functions and targets of let-7 micro rnas
WO2008073920A2 (en) 2006-12-08 2008-06-19 Asuragen, Inc. Mir-21 regulated genes and pathways as targets for therapeutic intervention
CN101622348A (zh) 2006-12-08 2010-01-06 奥斯瑞根公司 作为治疗性干预靶标的miR-20调节的基因和途径
WO2008073919A2 (en) 2006-12-08 2008-06-19 Asuragen, Inc. Mir-20 regulated genes and pathways as targets for therapeutic intervention
US20090175827A1 (en) 2006-12-29 2009-07-09 Byrom Mike W miR-16 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
CN103555825B (zh) 2007-01-31 2015-09-30 俄亥俄州立大学研究基金会 用于急性髓细胞白血病(aml)的诊断、预后和治疗的基于微rna的方法和组合物
ATE553196T1 (de) 2007-02-27 2012-04-15 Rosetta Genomics Ltd Zusammensetzung und verfahren zur modulation von zellproliferation und zelltod
JP5331714B2 (ja) 2007-03-16 2013-10-30 コヴァルクス・アーゲー タンパク質複合体をターゲティングする薬物候補の直接質量分析
US7745134B2 (en) 2007-04-10 2010-06-29 National Taiwan University Predicting post-treatment survival in cancer patients with microRNAs
WO2008136971A1 (en) 2007-04-30 2008-11-13 The Ohio State University Research Foundation Methods for differentiating pancreatic cancer from normal pancreatic function and/or chronic pancreatitis
US20090005336A1 (en) 2007-05-08 2009-01-01 Zhiguo Wang Use of the microRNA miR-1 for the treatment, prevention, and diagnosis of cardiac conditions
US20090131354A1 (en) 2007-05-22 2009-05-21 Bader Andreas G miR-126 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
US20090232893A1 (en) 2007-05-22 2009-09-17 Bader Andreas G miR-143 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
US20090099034A1 (en) 2007-06-07 2009-04-16 Wisconsin Alumni Research Foundation Reagents and Methods for miRNA Expression Analysis and Identification of Cancer Biomarkers
CA2689974A1 (en) 2007-06-08 2008-12-18 Asuragen, Inc. Mir-34 regulated genes and pathways as targets for therapeutic intervention
CN101711287B (zh) 2007-06-08 2016-04-27 由卫生与公众服务部代表的美利坚合众国政府 确定肝细胞癌亚型和检测肝癌干细胞的方法
AU2008266014B2 (en) 2007-06-15 2013-06-06 The Ohio State University Research Foundation Oncogenic ALL-1 fusion proteins for targeting drosha-mediated microRNA processing
EP2613149B1 (en) 2007-07-25 2014-09-17 University Of Louisville Research Foundation, Inc. Exosome-associated microRNA as a diagnostic marker
CN101809169B (zh) 2007-07-31 2013-07-17 俄亥俄州立大学研究基金会 通过靶向dnmt3a和dnmt3b恢复甲基化的方法
EP2173908B1 (en) 2007-08-03 2016-01-06 The Ohio State University Research Foundation Ultraconserved regions encoding ncrnas
CA2926831A1 (en) 2007-08-22 2009-02-26 The Ohio State University Research Foundation Methods and compositions for inducing deregulation of epha7 and erk phosphorylation in human acute leukemias
US20090061424A1 (en) 2007-08-30 2009-03-05 Sigma-Aldrich Company Universal ligation array for analyzing gene expression or genomic variations
CA2698771A1 (en) 2007-09-06 2009-03-12 The Ohio State University Research Foundation Microrna signatures in human ovarian cancer
US20090239818A1 (en) 2007-09-07 2009-09-24 Cheng Jin Q Effective treatment of ovarian cancer using triciribine and related compounds
EP2610342B1 (en) 2007-09-14 2016-05-04 The Ohio State University Research Foundation MiRNA Expression in Human Peripheral Blood Microvesicles and uses Thereof
WO2009044899A1 (ja) 2007-10-03 2009-04-09 Kyowa Hakko Kirin Co., Ltd. 細胞の増殖を制御する核酸
ES2463665T3 (es) 2007-10-04 2014-05-28 Stella Aps Tratamiento de combinación para el tratamiento de infección por virus de la hepatitis C
CN103937876B (zh) 2007-10-11 2016-08-17 俄亥俄州立大学研究基金会 用于诊断和治疗食管腺癌的方法和组合物
CA2703707A1 (en) 2007-10-26 2009-04-30 The Ohio State University Research Foundation Methods for identifying fragile histidine triad (fhit) interaction and uses thereof
CA2704043C (en) 2007-10-29 2018-09-18 Rosetta Genomics Ltd. Targeting micrornas for the treatment of liver cancer
WO2009064590A2 (en) 2007-11-12 2009-05-22 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Therapeutic applications of p53 isoforms in regenerative medicine, aging and cancer
US20090123933A1 (en) 2007-11-12 2009-05-14 Wake Forest University Health Sciences Microrna biomarkers in lupus
CN101918594A (zh) 2007-11-30 2010-12-15 俄亥俄州立大学研究基金会 肺癌中外周血中的微rna表达特征谱和靶向
WO2009070805A2 (en) 2007-12-01 2009-06-04 Asuragen, Inc. Mir-124 regulated genes and pathways as targets for therapeutic intervention
WO2009086156A2 (en) 2007-12-21 2009-07-09 Asuragen, Inc. Mir-10 regulated genes and pathways as targets for therapeutic intervention
CN101215560B (zh) 2007-12-26 2010-09-29 暨南大学 一种具有抗白血病作用的miR-21反义寡核苷酸及其应用
ES2936256T3 (es) 2008-02-01 2023-03-15 Massachusetts Gen Hospital Uso de microvesículas en el diagnóstico, y pronóstico de enfermedades y afecciones médicas
WO2009100430A2 (en) 2008-02-08 2009-08-13 Asuragen, Inc miRNAs DIFFERENTIALLY EXPRESSED IN LYMPH NODES FROM CANCER PATIENTS
CA2717026A1 (en) 2008-02-28 2009-09-03 The Ohio State University Research Foundation Microrna signatures associated with human chronic lymphocytic leukemia (ccl) and uses thereof
EP2250496A4 (en) 2008-02-28 2011-08-31 Univ Ohio State Res Found MICRO-RNA SIGNATURES ASSOCIATED WITH CYTOGENETICS AND PROGNOSIS IN ACUTE MYELOID LEUKEMIA (AML) AND USES THEREOF
US20110054009A1 (en) 2008-02-28 2011-03-03 The Ohio State University Research Foundation MicroRNA-Based Methods and Compositions for the Diagnosis, Prognosis and Treatment of Prostate Related Disorders
CA2716906A1 (en) 2008-02-28 2009-09-03 The Ohio State University Research Foundation Microrna-based methods and compositions for the diagnosis, prognosis and treatment of gastric cancer
WO2009111375A2 (en) 2008-03-01 2009-09-11 Abraxis Bioscience, Llc Treatment, diagnostic, and method for discovering antagonist using sparc specific mirnas
US20090233297A1 (en) * 2008-03-06 2009-09-17 Elizabeth Mambo Microrna markers for recurrence of colorectal cancer
WO2009154835A2 (en) 2008-03-26 2009-12-23 Asuragen, Inc. Compositions and methods related to mir-16 and therapy of prostate cancer
US20110166200A1 (en) 2008-04-24 2011-07-07 Zhan Zhang Methods of using mir210 as a biomarker for hypoxia and as a therapeutic agent for treating cancer
US8258111B2 (en) 2008-05-08 2012-09-04 The Johns Hopkins University Compositions and methods related to miRNA modulation of neovascularization or angiogenesis
WO2009147525A1 (en) 2008-06-04 2009-12-10 Karolinska Institutet Innovations Ab Skin cancer associated micrornas
WO2009149418A2 (en) 2008-06-06 2009-12-10 Asuragen, Inc. Novel compositions for the in vivo delivery of rnai agents
CA2727633A1 (en) 2008-06-11 2009-12-17 Xin W. Wang Use of mir-26 family as a predictive marker for hepatocellular carcinoma and responsiveness to therapy
US20100021734A1 (en) 2008-07-22 2010-01-28 Covalent Materials Corporation Ceramic particles and producing method thereof
KR101031305B1 (ko) 2008-07-23 2011-04-29 국립암센터 마이크로ｒｎａ-21 저해제를 포함하는 방사선 민감성증진용 조성물
US8492357B2 (en) 2008-08-01 2013-07-23 Santaris Pharma A/S Micro-RNA mediated modulation of colony stimulating factors
AU2009281969A1 (en) 2008-08-12 2010-02-18 The Ohio State University Research Foundation Micro-RNA-based compositions and methods for the diagnosis, prognosis and treatment of multiple myeloma
WO2010025928A1 (en) 2008-09-04 2010-03-11 Mtm Laboratories Ag Method for prediction of the progression risk of tumors
US20100179213A1 (en) 2008-11-11 2010-07-15 Mirna Therapeutics, Inc. Methods and Compositions Involving miRNAs In Cancer Stem Cells
US20110311555A1 (en) 2008-11-21 2011-12-22 The Ohio State University Tc11 as a Transcriptional Regulator
EP2373815A4 (en) 2008-12-05 2012-09-26 Univ Ohio State Res Found METHODS AND COMPOSITIONS BASED ON MICROARN FOR THE DIAGNOSIS AND TREATMENT OF OVARIAN CANCER
AU2010218147A1 (en) 2009-02-26 2011-10-20 The Government Of The United States Of America As Represented By The Secretary Of The Dept. Of Health & Human Services MicroRNAs in never-smokers and related materials and methods
CA2715518A1 (en) 2009-09-23 2011-03-23 Wilson Roa Microrna expression profiles associated with lung cancer
WO2011059776A2 (en) 2009-10-28 2011-05-19 Revision Therapeutics, Inc Prophylaxis of skin cancer with retinamides
US20120219958A1 (en) 2009-11-09 2012-08-30 Yale University MicroRNA Signatures Differentiating Uterine and Ovarian Papillary Serous Tumors
EP2504452A4 (en) 2009-11-23 2014-06-11 Univ Ohio State Res Found MATERIALS AND METHODS FOR INFLUENCING GROWTH, MIGRATION AND INVASION OF TUMOR CELLS
EP2354246A1 (en) 2010-02-05 2011-08-10 febit holding GmbH miRNA in the diagnosis of ovarian cancer
CN102844661B (zh) 2010-02-11 2014-06-25 香港理工大学 胃癌的生物标志物及其应用
AU2011232669B2 (en) 2010-03-26 2016-08-25 The Ohio State University Materials and methods related to modulation of mismatch repair and genomic stability by miR-155
CN103109183A (zh) 2010-06-24 2013-05-15 俄亥俄州立大学 通过靶向的miR-29表达建立的慢性淋巴细胞白血病小鼠模型
US20130150430A1 (en) 2010-08-04 2013-06-13 The Ohio State University Methods for Impairing the P53/HDM2 Auto-Regulatory Loop in Multiple Myeloma Development Using mIR-192, mIR-194 and mIR-215
CN103648505B (zh) 2010-11-12 2016-09-28 俄亥俄州立大学研究基金会 与微rna-21、错配修复和结肠直肠癌相关的材料和方法
WO2012097047A1 (en) 2011-01-11 2012-07-19 The Ohio State University Research Foundation Methods to identify chronic lymphocytic leukemia disease progression
CA2828772A1 (en) 2011-03-07 2012-09-13 The Ohio State University Mutator activity induced by microrna-155 (mir-155) links inflammation and cancer
EP2766500A4 (en) 2011-10-14 2015-10-14 Univ Ohio State METHOD AND MATERIALS IN CONNECTION WITH EGG CANCER
US8859202B2 (en) 2012-01-20 2014-10-14 The Ohio State University Breast cancer biomarker signatures for invasiveness and prognosis
US20130236453A1 (en) 2012-03-12 2013-09-12 The Ohio State University Methods and Compositions for Modulating Acute Graft-versus-Host Disease using miR-155 Specific Inhibitors

Also Published As

Publication number Publication date
US20120214690A1 (en) 2012-08-23
CN103642900B (zh) 2016-04-13
ES2525584T3 (es) 2014-12-26
EP2479285B1 (en) 2014-05-14
EP2505669A3 (en) 2013-02-13
EP2487256A2 (en) 2012-08-15
CN101389770B (zh) 2013-11-06
AU2007205163B2 (en) 2013-07-25
EP2484782A1 (en) 2012-08-08
US9017940B2 (en) 2015-04-28
EP2468898A3 (en) 2013-03-06
EP2479286A1 (en) 2012-07-25
ES2545118T3 (es) 2015-09-08
US8148069B2 (en) 2012-04-03
JP5395439B2 (ja) 2014-01-22
US20080306006A1 (en) 2008-12-11
EP2487255A2 (en) 2012-08-15
EP2468899A2 (en) 2012-06-27
EP2487262B1 (en) 2014-12-10
EP2487262A2 (en) 2012-08-15
EP2487262A3 (en) 2012-11-28
EP2468891B1 (en) 2015-04-29
US9051618B2 (en) 2015-06-09
EP2487252B1 (en) 2014-10-15
US8512951B2 (en) 2013-08-20
ES2536437T3 (es) 2015-05-25
EP2468897A3 (en) 2013-02-27
EP2487261B1 (en) 2015-07-01
EP2487253B1 (en) 2015-06-24
EP2468893B1 (en) 2015-03-11
ES2508893T3 (es) 2014-10-16
ES2536422T3 (es) 2015-05-25
EP2487261A3 (en) 2012-11-07
EP2487260A2 (en) 2012-08-15
US8658362B2 (en) 2014-02-25
US20160215352A1 (en) 2016-07-28
ES2440787T3 (es) 2014-01-30
US20120214688A1 (en) 2012-08-23
WO2007081740A3 (en) 2008-07-10
EP2468896A3 (en) 2013-03-06
US20120214692A1 (en) 2012-08-23
US20120214700A1 (en) 2012-08-23
US20130331439A1 (en) 2013-12-12
CA2633754C (en) 2013-06-18
EP2479285A1 (en) 2012-07-25
EP2468894A3 (en) 2013-02-27
US20130324589A1 (en) 2013-12-05
EP2471956A1 (en) 2012-07-04
ES2527592T3 (es) 2015-01-27
US20140100133A1 (en) 2014-04-10
US8580500B2 (en) 2013-11-12
EP1969147A4 (en) 2009-11-25
US20120214703A1 (en) 2012-08-23
US20120214689A1 (en) 2012-08-23
EP2484783A1 (en) 2012-08-08
EP2468892A2 (en) 2012-06-27
EP2468891A2 (en) 2012-06-27
EP2487254A3 (en) 2012-09-26
EP2468890B1 (en) 2014-03-19
EP2468893A3 (en) 2012-11-07
EP2487261A2 (en) 2012-08-15
EP2487258B1 (en) 2014-10-01
ES2546425T3 (es) 2015-09-23
US9017939B2 (en) 2015-04-28
EP2487254B1 (en) 2015-07-29
US20120214701A1 (en) 2012-08-23
EP2487259A3 (en) 2012-10-24
EP2505669A2 (en) 2012-10-03
EP2468898B1 (en) 2015-03-11
EP2468890A2 (en) 2012-06-27
CN101389770A (zh) 2009-03-18
ES2490995T3 (es) 2014-09-04
ES2545360T3 (es) 2015-09-10
EP2468895A2 (en) 2012-06-27
EP2505668A2 (en) 2012-10-03
EP2468890A3 (en) 2012-10-17
EP2487252A3 (en) 2012-08-22
EP2468897A2 (en) 2012-06-27
US20120214702A1 (en) 2012-08-23
ES2465600T3 (es) 2014-06-06
ES2545119T3 (es) 2015-09-08
EP2471958A1 (en) 2012-07-04
CN103642900A (zh) 2014-03-19
CN105907842A (zh) 2016-08-31
EP2468893A2 (en) 2012-06-27
US20140018412A1 (en) 2014-01-16
US20120214696A1 (en) 2012-08-23
US9023598B2 (en) 2015-05-05
EP2487253A2 (en) 2012-08-15
ES2604324T3 (es) 2017-03-06
EP2468895A3 (en) 2013-02-27
US20120214698A1 (en) 2012-08-23
EP2484782B1 (en) 2015-11-18
JP2016025853A (ja) 2016-02-12
EP2487258A2 (en) 2012-08-15
EP2487254A2 (en) 2012-08-15
US20120214691A1 (en) 2012-08-23
EP2487257A3 (en) 2012-10-17
EP2468894A2 (en) 2012-06-27
EP2468894B1 (en) 2014-12-10
JP2014060993A (ja) 2014-04-10
EP2468898A2 (en) 2012-06-27
EP2487253A3 (en) 2012-08-22
EP2487260B1 (en) 2015-07-08
EP2487257B1 (en) 2015-07-01
US8507202B2 (en) 2013-08-13
US8603744B2 (en) 2013-12-10
US20120214694A1 (en) 2012-08-23
EP2505668A3 (en) 2013-01-09
EP2487252A2 (en) 2012-08-15
ES2531052T3 (es) 2015-03-10
EP2468899B1 (en) 2015-03-11
US20140018411A1 (en) 2014-01-16
US20160186177A1 (en) 2016-06-30
EP2487256B1 (en) 2015-07-01
ES2461189T3 (es) 2014-05-19
EP2468899A3 (en) 2013-02-27
EP2487263A2 (en) 2012-08-15
EP2468892A3 (en) 2012-10-31
EP2487260A3 (en) 2012-11-07
EP2487256A3 (en) 2012-10-17
US20120214697A1 (en) 2012-08-23
JP5743982B2 (ja) 2015-07-01
ES2544713T3 (es) 2015-09-03
US8557520B2 (en) 2013-10-15
EP2468896A2 (en) 2012-06-27
US20120214693A1 (en) 2012-08-23
US20120214695A1 (en) 2012-08-23
AU2007205163A1 (en) 2007-07-19
ES2557411T3 (es) 2016-01-25
EP2468895B1 (en) 2014-09-24
WO2007081740A2 (en) 2007-07-19
EP2484783B1 (en) 2016-10-12
CA2633754A1 (en) 2007-07-19
EP1969147B1 (en) 2014-07-30
ES2536423T3 (es) 2015-05-25
ES2547805T3 (es) 2015-10-08
EP2487255A3 (en) 2012-10-10
JP2009531019A (ja) 2009-09-03
EP1969147A2 (en) 2008-09-17
EP2487258A3 (en) 2012-10-24
JP2013046612A (ja) 2013-03-07
JP5837909B2 (ja) 2015-12-24
HK1132302A1 (en) 2010-02-19
EP2487263B1 (en) 2014-03-19
EP2487259A2 (en) 2012-08-15
EP2487257A2 (en) 2012-08-15
EP2487263A3 (en) 2012-10-17
ES2537880T3 (es) 2015-06-15
EP2487259B1 (en) 2015-07-01
ES2526787T3 (es) 2015-01-15
US20120214699A1 (en) 2012-08-23
EP2479286B1 (en) 2013-11-13
EP2468891A3 (en) 2012-11-21

Similar Documents

Publication Publication Date Title
ES2527592T3 (es) Métodos basados en microARN para el diagnóstico del cáncer de colon
EP3683320A3 (en) Mirna fingerprint in the diagnosis of lung cancer
NZ578283A (en) Proteomic profiling method useful for condition diagnosis and monitoring, composition screening, and therapeutic monitoring
WO2007103808A3 (en) Microrna expression profile associated with pancreatic cancer
EP4219760A3 (en) Methods, compositions, and devices utilizing microrna to determine physiological conditions
WO2011015944A3 (en) Use of free dna as an early predictor of severity in acute pancreatitis
BR122018069446B8 (pt) método in vitro para detectar a presença de um célula de câncer em um indivíduo
WO2010091049A3 (en) Diagnosis and treatment of cancer
ES2570359T3 (es) Regiones ultraconservadas que codifican ARNnc
GB2459228A (en) Exosome-associated microrna as a diagnostic marker
GB2467704A (en) Methods of monitoring conditions by sequence analysis
BR112012009262A2 (pt) ''método para inibir a proliferação de células de câncer positivo para ar em um indivíduo diagnosticado com,ou qual se suspeita que tenha cânce positivo para ar e método para identificar se um indivíduo é um candidato para tratamento com uma composiçâo
NZ607282A (en) Method for using gene expression to determine prognosis of prostate cancer
BRPI0507442B8 (pt) método in vitro de diagnóstico de um indivíduo humano gestante como apresentando ou com uma propensão a desenvolver pré-eclâmpsia ou eclâmpsia
MX355020B (es) Biomarcadores de cancer de pulmon y usos de los mismos.
PT1597391E (pt) Utilização de arn intrónico para medir a expressão genética
WO2012018535A3 (en) Wellness panel
GB0603251D0 (en) DNA conformation
MX341840B (es) Biomarcadores de microarn indicativos de la enfermedad de alzheimer.
MX2009013649A (es) Variantes geneticas en el cromosoma 15q24 como marcadores para usarse en diagnostico, prognosis y tratamiento de sindrome de exfoliacion y glaucoma.
NZ595356A (en) Methods of predicting cancer risk using gene expression in premalignant tissue
NZ602369A (en) Anti-cxcr1 compositions and methods
EP2021794B8 (en) Use of protein s100a 12 as a marker for colorectal cancer
EA200801046A1 (ru) Неинвазивный способ выявления переходно-клеточной карциномы мочевого пузыря in vitro
WO2010037859A3 (en) Methods for predicting or monitoring whether a patient affected by a cancer is responsive to a treatment with a molecule of the taxoid family